NAREB Workshop

Nanomedicine & antibiotic resistance

17 November 2017, Residencia de Estudiantes, Madrid, Spain

 

Increase in antibiotic resistance is a global concern worldwide. The portofolio of available antibiotics for treating antibiotic resistant bacterial infections is very limited and comprises of molecules inducing severe side effects and/or difficult to administrate. New tools that provide better efficacy are urgently needed for a faster, more efficient, and less impairing treatment.

In this context, the NAREB project aims to propose nanotechnology solutions to the problem of Multi-drug resistant Mycobacterium tuberculosis as well as methicillin resistant Staphylococcus aureus.

Join the communities of infectious diseases and nanotechnologies to learn and discuss about antibiotic resistance, nanomedicine and the use of the nanotechnologies to fight infectious diseases as well as other diseases. You will also have the opportunity to discover pre-clinical models to test nanomedicines. The coordinators of three EU-Funded projects on nanomedicine and antibiotic resistance (FORMAMP, NAREB and PneumoNP) will also present their success and difficulties in developing nanomedicine for antibiotic-resistant infectious diseases.

 

Keynotes speakers:

  • Fernando Baquero (IRYCIS, Spain) - Antibiotic resistance: the role of minorities
  • Jose Luis Martinez (CSIC, Spain)- One-Health approches for fighting antibiotic resistance
  • Gert Storm (Utrecht University, The Netherlands) - Targeted Nanomedicine: Clinical State-of-the-Art

Session topics:

  • Preclinical models: how to test new formulations or new molecules
  • Lessions learned from the cluster projects (FORMAM, NAREB & PneumoNP)
  • Nanotechnologies for infectious diseases versus other diseases

 

View the full program and practical information here.

Download the flyer here.

Location :

Residencia de Estudiantes - Calle del Pinar, 21-23 - 28006 Madrid, Spain

Room: Salon de actos

locationOK

 

 

eu-fev2014-2

The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.